Peregrine Pharmaceuticals Reports First Quarter Fiscal Year 2013 Financial Results and Recent Developments

Interim Data From Peregrine's Phase II Trial in Second-Line Non-Small Cell Lung Cancer Demonstrate Doubling of Median Overall Survival in Bavituximab-Containing Arms

Peregrine to Report First Quarter Fiscal Year 2013 Financial Results Before Market on September 10, 2012

Data From Peregrine's Phase II Bavituximab Second-Line Lung Cancer Trial to Be Highlighted in Late-Breaking Oral Presentation at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology

Peregrine Pharmaceuticals Secures $30 Million Loan Facility

Peregrine to Present at Stifel Nicolaus Healthcare Conference September 5, 2012 at 2:40 PM EDT

Peregrine to Present at Wedbush Securities Life Sciences Management Access Conference on August 15, 2012 at 10:55 AM EDT

Peregrine Regains Compliance With NASDAQ Minimum Bid Price Listing Requirement

Peregrine Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2012 Financial Results and Recent Developments

Peregrine Announces Initiation of a Phase I Rectal Adenocarcinoma Investigator-Sponsored Trial